
# Arbeidserfaring

# Mastergrad

Master i Teknologi Norges Teknisk-Naturvitenskapelige Universitet
Sivilingeniør Fysikk og Matematikk, spesialisering Biofysikk og Medisinsk teknologi
Tittel på masteroppgave: Tumor Dosimetry in a Phase I Study of Lu(177)-DOTA-HH1 (Betalutin) - How hard does the magic bullet strike? (2010-2015)

# Publikasjoner

"Tumor Absorbed Dose for non-Hodgkin's Lymphoma Patients treated with the novel anti-CD37 antibody radionuclide conjugate 177Lu-lilotomab satetraxetan." The Journal of Nuclear Medicine, doi: 10.2967/jnumed.116.173922

"Red Marrow Absorbed Dose for non-Hodgkin's Lymphoma Patients treated with the novel anti-CD37 antibody radionuclide conjugate 177Lu-lilotomab satetraxetan." The Journal of Nuclear Medicine doi: 10.2967/jnumed.116.180471

"Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the AntibodyRadionuclide Conjugate 177Lu-Lilotomab Satetraxetan." The Journal of Nuclear Medicine doi: 10.2967/jnumed.117.195347

"Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients." European Journal of Nuclear Medicine and Molecular Imaging.  doi: 10.2967/jnumed.116.180471

# Konferansedeltagelse:

NSNM 2019
EANM 2018
ECNMP 2018
NSNM 2018
EANM 2017
EANM 2016

"Dosimetric methods in a new radioimmunotherapy"  MedFys 2015, Kvitfjell
Posterpresentasjon

"Pre-Dosing with Cold Antibody (HH1) Reduces Red Bone Marrow Absorbed Doses in Patients Treated with the Novel Antibody-Radionuclide-Conjugate 177-Lu-DOTA-HH1" - EANM 2016, Barcelona, Poster (Highlighted)

"Pre-dosing with lilotomab prior to antibody-radionuclide conjugate therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumour to red marrow absorbed dose in non-Hodgkin lymphoma patients" - EANM 2017, Wien, Poster (Highlighted, Nominert til Marie Curie-prisen)


